RESEARCH

Silencing DNA repair genes with nanoparticles restores immune response in microsatellite-stable colorectal cancer — Molecular Cancer

Microsatellite-stable (MSS) colorectal cancer, which represents the majority of cases, typically does not respond to immunotherapy because it has a low tumor mutational burden. Researchers developed lipid nanoparticles carrying small interfering RNA (siRNA) that silence key mismatch repair genes (MLH1, MSH2, and MSH6), achieving over 70% gene silencing in mouse models of MSS colorectal cancer. When combined with oxaliplatin chemotherapy, this approach substantially increased tumor mutational burden, expanded the repertoire of tumor-derived neoantigens, and promoted CD8+ T cell infiltration and activation. This combinatorial regimen effectively inhibited tumor progression in pMMR/MSS CRC across both subcutaneous and liver metastasis mouse models.

What this means

This preclinical strategy offers a potential path to make the majority of colorectal cancers, those that are microsatellite-stable, responsive to immunotherapy by artificially increasing their mutational burden. The approach remains investigational and has not yet been tested in human trials.